We are developing a safe, effective, immunological-based treatment for a range of hard-to-treat solid tumours
Over eight years, under the leadership of Professor Delia Nelson at Curtin University’s Faculty of Health Sciences, Selvax has achieved a major breakthrough in cancer treatment.
Selvax’s self-vaccine cancer immunotherapy harnesses the body’s anti-tumour immune response.
By combining two immunological agents approved for use in humans, administered directly into the tumour site, we have achieved complete regression of large, chemotherapy-resistant tumours without toxicity.